127 related articles for article (PubMed ID: 20802100)
1. Commentary.
Bennett ST
Clin Chem; 2010 Sep; 56(9):1393. PubMed ID: 20802100
[No Abstract] [Full Text] [Related]
2. Commentary.
Sinclair D
Clin Chem; 2010 Sep; 56(9):1392. PubMed ID: 20802099
[No Abstract] [Full Text] [Related]
3. A healthy young man presenting with multiple rib fractures.
Harle L; Chan C; Bhagavan NV; Rios CN; Sugiyama CE; Loscalzo M; Uyehara-Lock J; Honda SA
Clin Chem; 2010 Sep; 56(9):1390-2. PubMed ID: 20802098
[No Abstract] [Full Text] [Related]
4. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the heavy/light-chain assay for the diagnosis and monitoring of multiple myeloma.
Chae H; Cha K; Kim M; Kim Y; Min CK
Int J Lab Hematol; 2013 Oct; 35(5):e10-2. PubMed ID: 23311353
[No Abstract] [Full Text] [Related]
6. Immunoglobulin heavy and light chain isotypes in multiple myeloma patients.
Ansari NA; Owais M; Usha
Asian Pac J Cancer Prev; 2007; 8(4):593-6. PubMed ID: 18260735
[TBL] [Abstract][Full Text] [Related]
7. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
8. Detecting only light chains, now what?
Jacobs JF; Joosten I; Klasen IS
Clin Chem; 2010 Aug; 56(8):1368. PubMed ID: 20668174
[No Abstract] [Full Text] [Related]
9. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
[No Abstract] [Full Text] [Related]
10. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.
Ludwig H; Milosavljevic D; Berlanga O; Zojer N; Hübl W; Fritz V; Harding S
Am J Hematol; 2016 Mar; 91(3):295-301. PubMed ID: 26662888
[TBL] [Abstract][Full Text] [Related]
12. IgD-lambda myeloma with separate heavy- and light-chain M-components.
Vilpo JA; Irjala K
Clin Chem; 1980 Nov; 26(12):1760-1. PubMed ID: 6775847
[No Abstract] [Full Text] [Related]
13. Heavy/light chain assay for monitoring IgA multiple myeloma: digging out the IgA from the β region.
Calderon B
Clin Chem; 2015 Feb; 61(2):317-8. PubMed ID: 25501934
[No Abstract] [Full Text] [Related]
14. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
15. Sensitive multiple myeloma disease monitoring by mass spectrometry.
Santockyte R; Jin C; Pratt J; Ammar R; Desai K; Bolisetty M; Das P; Popa-McKiver M; Puig O
Blood Cancer J; 2021 Apr; 11(4):78. PubMed ID: 33927186
[No Abstract] [Full Text] [Related]
16. Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response.
D'Auria F; La Rocca F; Simeon V; Statuto T; Pietrantuono G; D'Arena G; Villani O; Mansueto G; Traficante A; Musto P
Br J Haematol; 2018 May; 181(4):550-552. PubMed ID: 28439880
[No Abstract] [Full Text] [Related]
17. Correlations among different markers determined by immunochemical methods used for the diagnosis and monitoring of intact immunoglobulin multiple myeloma cases.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2012; 71(4):183-200. PubMed ID: 23755700
[TBL] [Abstract][Full Text] [Related]
18. Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay.
Kamiya Y; Chou T; Murakami H; Handa H; Ozaki S; Shimazaki C; Fuchida SI; Okada J; Itoh J; Sugiyama S; Shimizu K
Hematol Oncol; 2019 Aug; 37(3):316-318. PubMed ID: 30938836
[No Abstract] [Full Text] [Related]
19. A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains.
Katzmann JA; Rajkumar SV
Leukemia; 2013 Jan; 27(1):1-2. PubMed ID: 23299499
[No Abstract] [Full Text] [Related]
20. Heavy/Light-chain analysis of monoclonal gammopathies.
Keren DF
Clin Chem; 2009 Sep; 55(9):1606-8. PubMed ID: 19589841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
